Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease - Resemblance to the effect of amphetamine drugs of abuse

Free Radical Biology and Medicine

Volumn 53, Issue 9, 2012, Pages 1791-1806

  Perfeito, Rita ^a   Cunha Oliveira, Teresa ^a   Rego, Ana Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Amphetamines; Dopamine; Free radicals; Mitochondrial dysfunction; Oxidative stress; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; AMPHETAMINE; DJ 1 PROTEIN; DOPAMINE; LEUCINE RICH REPEAT KINASE 2; PARKIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UBIQUITIN;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CYTOPLASM; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DJ 1 GENE; DOPAMINERGIC NERVE CELL; DRUG ABUSE; ENVIRONMENTAL FACTOR; EXCITOTOXICITY; GENE; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; LEWY BODY; LONG TERM EXPOSURE; LRRK2 GENE; MORPHOLOGY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARK2 GENE; PARKINSON DISEASE; PATHOGENESIS; PINK1 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RESPIRATORY CHAIN; REVIEW; SNCA GENE;

AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84867397192     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.08.569     Document Type: Review

References (318)

1. M.C. de Rijk, L.J. Launer, K. Berger, M.M. Breteler, J.F. Dartigues, and M. Baldereschi Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group Neurology 54 2000 S21 S23
2. L.M. Bekris, I.F. Mata, and C.P. Zabetian The genetics of Parkinson disease J. Geriatr. Psychiatry Neurol. 23 2010 228 242
3. A.N. Sellbach, R.S. Boyle, P.A. Silburn, and G.D. Mellick Parkinson's disease and family history Parkinsonism Relat. Disord. 12 2006 399 409
4. M.J. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects Nat. Rev. Genet. 7 2006 306 318
5. L.M. de Lau, and M.M. Breteler Epidemiology of Parkinson's disease Lancet Neurol. 5 2006 525 535
6. R.B. Mounsey, and P. Teismann Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection Parkinsons Dis 617472 2011 2010
7. A.H. Schapira Etiology and pathogenesis of Parkinson disease Neurol. Clin. 27 2009 583 603 v
8. A.H. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease J. Neurochem. 54 1990 823 827
9. A.H. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease Lancet 1 1989 1269
10. D.T. Dexter, P. Jenner, A.H. Schapira, and C.D. Marsden Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group Ann. Neurol 32 Suppl 1992 S94 100
11. A.D. Owen, A.H. Schapira, P. Jenner, and C.D. Marsden Oxidative stress and Parkinson's disease Ann. N. Y. Acad. Sci. 786 1996 217 223
12. V.M. Mann, J.M. Cooper, and A.H. Schapira Quantitation of a mitochondrial DNA deletion in Parkinson's disease FEBS Lett 299 1992 218 222
13. A.H. Schapira Oxidative stress in Parkinson's disease Neuropathol. Appl. Neurobiol. 21 1995 3 9
14. M. Gu, A.D. Owen, S.E. Toffa, J.M. Cooper, D.T. Dexter, and P. Jenner Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases J. Neurol. Sci. 158 1998 24 29
15. A.H. Schapira Challenges to the development of disease-modifying therapies in Parkinson's disease Eur. J. Neurol 18 Suppl. 1 2011 16 21
16. A.C. Rego, and C.R. Oliveira Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases Neurochem. Res 28 2003 1563 1574
17. D.W. Dickson, H. Braak, J.E. Duda, C. Duyckaerts, T. Gasser, and G.M. Halliday Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria Lancet Neurol. 8 2009 1150 1157
18. G. Halliday, A. Lees, and M. Stern Milestones in Parkinson's disease - clinical and pathologic features Mov. Disord 26 2011 1015 1021
19. J.M. Fearnley, and A.J. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 Pt 5 1991 2283 2301
20. C.J. Dunning, J.F. Reyes, J.A. Steiner, and P. Brundin Can Parkinson's disease pathology be propagated from one neuron to another? Prog. Neurobiol 97 2012 205 219
21. A. Samii, J.G. Nutt, and B.R. Ransom Parkinson's disease Lancet 363 2004 1783 1793
22. George J.M. The synucleins. Genome Biol. 3:reviews3002; 2002.
23. A. Probst, A. Bloch, and M. Tolnay New insights into the pathology of Parkinson's disease: does the peripheral autonomic system become central? Eur. J. Neurol 15 Suppl. 1 2008 1 4
24. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov. Disord 26 2011 1049 1055
25. D.C. Poskanzer, and R.S. Schwab Cohort analysis of Parkinson's syndrome: evidence for a single etiology related to subclinical infection about 1920 J. Chronic Dis 16 1963 961 973
26. O. Corti, S. Lesage, and A. Brice What genetics tells us about the causes and mechanisms of Parkinson's disease Physiol. Rev 91 2011 1161 1218
27. J. Lotharius, and K.L. O'Malley Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity Ann. Neurol 49 2001 79 89
28. L.K. Klaidman, J.D. Adams Jr., A.C. Leung, S.S. Kim, and E. Cadenas Redox cycling of MPP: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase Free Radic. Biol. Med. 15 1993 169 179
29. J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 1983 979 980
30. O.A. Ross, A.T. Braithwaite, L.M. Skipper, J. Kachergus, M.M. Hulihan, and F.A. Middleton Genomic investigation of α-synuclein multiplication and parkinsonism Ann. Neurol. 63 2008 743 750
31. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
32. T.B. Sherer, J.H. Kim, R. Betarbet, and J.T. Greenamyre Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation Exp. Neurol 179 2003 9 16
33. T.B. Sherer, R. Betarbet, C.M. Testa, B.B. Seo, J.R. Richardson, and J.H. Kim Mechanism of toxicity in rotenone models of Parkinson's disease J. Neurosci. 23 2003 10756 10764
34. D.A. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2 2003 531 538
35. A. Elbaz, and F. Moisan Update in the epidemiology of Parkinson's disease Curr. Opin. Neurol. 21 2008 454 460
36. A. Ascherio, S.M. Zhang, M.A. Hernan, I. Kawachi, G.A. Colditz, and F.E. Speizer Prospective study of caffeine consumption and risk of Parkinson's disease in men and women Ann. Neurol 50 2001 56 63
37. T.T. Warner, and A.H. Schapira Genetic and environmental factors in the cause of Parkinson's disease Ann. Neurol 53 Suppl. 3 2003 S16 S23
38. M.H. Polymeropoulos, J.J. Higgins, L.I. Golbe, W.G. Johnson, S.E. Ide, and I.G. Di Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 Science 274 1996 1197 1199
39. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the α-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
40. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert α-Synuclein in Lewy bodies Nature 388 1997 839 840
41. A.C. Belin, and M. Westerlund Parkinson's disease: a genetic perspective FEBS J 275 2008 1377 1383
42. W. Satake, Y. Nakabayashi, I. Mizuta, Y. Hirota, C. Ito, and M. Kubo Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease Nat. Genet 41 2009 1303 1307
43. J. Simon-Sanchez, C. Schulte, J.M. Bras, M. Sharma, J.R. Gibbs, and D. Berg Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat. Genet 41 2009 1308 1312
44. N. Pankratz, J.B. Wilk, J.C. Latourelle, A.L. DeStefano, C. Halter, and E.W. Pugh Genomewide association study for susceptibility genes contributing to familial Parkinson disease Hum. Genet. 124 2009 593 605
45. T.H. Hamza, C.P. Zabetian, A. Tenesa, A. Laederach, J. Montimurro, and D. Yearout Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease Nat. Genet 42 2010 781 785
46. C. Paisan-Ruiz, K.P. Bhatia, A. Li, D. Hernandez, M. Davis, and N.W. Wood Characterization of PLA2G6 as a locus for dystonia-parkinsonism Ann. Neurol. 65 2009 19 23
47. F.A. Di, M.C. Dekker, P. Montagna, A. Baruzzi, E.H. Yonova, and G.L. Correia FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome Neurology 72 2009 240 245
48. A.A. Hicks, H. Petursson, T. Jonsson, H. Stefansson, H.S. Johannsdottir, and J. Sainz A susceptibility gene for late-onset idiopathic Parkinson's disease Ann. Neurol. 52 2002 549 555
49. C. Lautier, S. Goldwurm, A. Durr, B. Giovannone, W.G. Tsiaras, and G. Pezzoli Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease Am. J. Hum. Genet. 82 2008 822 833
50. E. Leroy, R. Boyer, G. Auburger, B. Leube, G. Ulm, and E. Mezey The ubiquitin pathway in Parkinson's disease Nature 395 1998 451 452
51. T. Gasser, B. Muller-Myhsok, Z.K. Wszolek, R. Oehlmann, D.B. Calne, and V. Bonifati A susceptibility locus for Parkinson's disease maps to chromosome 2p13 Nat. Genet 18 1998 262 265
52. K.M. Strauss, L.M. Martins, H. Plun-Favreau, F.P. Marx, S. Kautzmann, and D. Berg Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease Hum. Mol. Genet 14 2005 2099 2111
53. N. Pankratz, W.C. Nichols, S.K. Uniacke, C. Halter, J. Murrell, and A. Rudolph Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families Hum. Mol. Genet 12 2003 2599 2608
54. S. Lesage, and A. Brice Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum. Mol. Genet 18 2009 R48 R59
55. C. Paisan-Ruiz LRRK2 gene variation and its contribution to Parkinson disease Hum. Mutat 30 2009 1153 1160
56. K. Kosaka, K. Tsuchiya, and M. Yoshimura Lewy body disease with and without dementia: a clinicopathological study of 35 cases Clin. Neuropathol 7 1988 299 305
57. H. Braak, E. Braak, D. Yilmazer, C. Schultz, R.A. de Vos, and E.N. Jansen Nigral and extranigral pathology in Parkinson's disease J. Neural Transm. Suppl. 46 1995 15 31
58. V. Macdonald, and G.M. Halliday Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease Mov. Disord 17 2002 1166 1173
59. J.M. Henderson, K. Carpenter, H. Cartwright, and G.M. Halliday Degeneration of the centre median-parafascicular complex in Parkinson's disease Ann. Neurol 47 2000 345 352
60. D.A. McRitchie, H.R. Cartwright, and G.M. Halliday Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease Exp. Neurol 144 1997 202 213
61. N.I. Bohnen, and R.L. Albin The cholinergic system and Parkinson disease Behav. Brain Res. 221 2011 564 573
62. R. Fronczek, S. Overeem, S.Y. Lee, I.M. Hegeman, P.J. van, and S.G. van Duinen Hypocretin (orexin) loss in Parkinson's disease Brain 130 2007 1577 1585
63. T.C. Thannickal, Y.Y. Lai, and J.M. Siegel Hypocretin (orexin) cell loss in Parkinson's disease Brain 130 2007 1586 1595
64. G.M. Halliday, Y.W. Li, P.C. Blumbergs, T.H. Joh, R.G. Cotton, and P.R. Howe Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease Ann. Neurol. 27 1990 373 385
65. A.J. Harding, E. Stimson, J.M. Henderson, and G.M. Halliday Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease Brain 125 2002 2431 2445
66. A.E. Kingsbury, R. Bandopadhyay, L. Silveira-Moriyama, H. Ayling, C. Kallis, and W. Sterlacci Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model Mov. Disord 25 2010 2508 2515
67. W.J. Hoogendijk, C.W. Pool, D. Troost, Z.E. van, and D.F. Swaab Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis Brain 118 Pt 1 1995 131 143
68. K.M. Pedersen, L. Marner, H. Pakkenberg, and B. Pakkenberg No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study Mov. Disord 20 2005 164 171
69. K.L. Double, G.M. Halliday, D.A. McRitchie, W.G. Reid, M.A. Hely, and J.G. Morris Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease Dementia 7 1996 304 313
70. T.O. Dalaker, R. Zivadinov, J.P. Larsen, M.K. Beyer, J.L. Cox, and G. Alves Gray matter correlations of cognition in incident Parkinson's disease Mov. Disord 25 2010 629 633
71. H. Braak, T.K. Del, H. Bratzke, J. Hamm-Clement, D. Sandmann-Keil, and U. Rub Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J. Neurol. 249 Suppl. 3 2002 III/1-III/5
72. H. Braak, T.K. Del, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
73. H. Braak, E. Ghebremedhin, U. Rub, H. Bratzke, and T.K. Del Stages in the development of Parkinson's disease-related pathology Cell Tissue Res 318 2004 121 134
74. J.E. Duda, V.M. Lee, and J.Q. Trojanowski Neuropathology of synuclein aggregates J. Neurosci. Res. 61 2000 121 127
75. G.M. Halliday, and H. McCann The progression of pathology in Parkinson's disease Ann. N. Y. Acad. Sci. 1184 2010 188 195
76. C.H. Hawkes, T.K. Del, and H. Braak A timeline for Parkinson's disease Parkinsonism Relat. Disord. 16 2010 79 84
77. P. Brundin, J.Y. Li, J.L. Holton, O. Lindvall, and T. Revesz Research in motion: the enigma of Parkinson's disease pathology spread Nat. Rev. Neurosci. 9 2008 741 745
78. M.E. Kalaitzakis, M.B. Graeber, S.M. Gentleman, and R.K. Pearce The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging Neuropathol. Appl. Neurobiol 34 2008 284 295
79. J. Attems, and K.A. Jellinger The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease Neuropathol. Appl. Neurobiol 34 2008 466 467
80. A.H. Tsang, and K.K. Chung Oxidative and nitrosative stress in Parkinson's disease Biochim. Biophys. Acta 1792 2009 643 650
81. S.R. Danielson, and J.K. Andersen Oxidative and nitrative protein modifications in Parkinson's disease Free Radic. Biol. Med. 44 2008 1787 1794
82. R.C. Seet, C.Y. Lee, E.C. Lim, J.J. Tan, A.M. Quek, and W.L. Chong Oxidative damage in Parkinson disease: measurement using accurate biomarkers Free Radic. Biol. Med. 48 2010 560 566
83. A. Navarro, and A. Boveris Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease J. Bioenerg. Biomembr 41 2009 517 521
84. R. Betarbet, T.B. Sherer, G. MacKenzie, M. Garcia-Osuna, A.V. Panov, and J.T. Greenamyre Chronic systemic pesticide exposure reproduces features of Parkinson's disease Nat. Neurosci. 3 2000 1301 1306
85. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, and A. Lees Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J. Neurochem 52 1989 381 389
86. A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E.R. Stadtman, and Y. Mizuno Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease Proc. Natl. Acad. Sci. USA 93 1996 2696 2701
87. Z.I. Alam, A. Jenner, S.E. Daniel, A.J. Lees, N. Cairns, and C.D. Marsden Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra J. Neurochem 69 1997 1196 1203
88. J. Zhang, G. Perry, M.A. Smith, D. Robertson, S.J. Olson, and D.G. Graham Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons Am. J. Pathol 154 1999 1423 1429
89. Z.I. Alam, S.E. Daniel, A.J. Lees, D.C. Marsden, P. Jenner, and B. Halliwell A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease J. Neurochem 69 1997 1326 1329
90. E. Floor, and M.G. Wetzel Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay J. Neurochem 70 1998 268 275
91. P.F. Good, A. Hsu, P. Werner, D.P. Perl, and C.W. Olanow Protein nitration in Parkinson's disease J. Neuropathol. Exp. Neurol. 57 1998 338 342
92. J.E. Duda, B.I. Giasson, Q. Chen, T.L. Gur, H.I. Hurtig, and M.B. Stern Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies Am. J. Pathol. 157 2000 1439 1445
93. R.J. Ferrante, P. Hantraye, E. Brouillet, and M.F. Beal Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase Brain Res 823 1999 177 182
94. S. Pennathur, V. Jackson-Lewis, S. Przedborski, and J.W. Heinecke Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease J. Biol. Chem 274 1999 34621 34628
95. T.L. Perry, D.V. Godin, and S. Hansen Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33 1982 305 310
96. T.L. Perry, and V.W. Yong Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients Neurosci. Lett 67 1986 269 274
97. R.K. Pearce, A. Owen, S. Daniel, P. Jenner, and C.D. Marsden Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease J. Neural Transm 104 1997 661 677
98. E.C. Hirsch Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol 32 Suppl 1992 S88 S93
99. D. Sulzer Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease Trends Neurosci 30 2007 244 250
100. L. Zecca, D. Tampellini, M. Gerlach, P. Riederer, R.G. Fariello, and D. Sulzer Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour Mol. Pathol 54 2001 414 418
101. D.T. Dexter, F.R. Wells, A.J. Lees, F. Agid, Y. Agid, and P. Jenner Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J. Neurochem 52 1989 1830 1836
102. J.M. Gutteridge Hydroxyl radicals, iron, oxidative stress, and neurodegeneration Ann. N. Y. Acad. Sci. 738 1994 201 213
103. L. Zecca, L. Casella, A. Albertini, C. Bellei, F.A. Zucca, and M. Engelen Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease J. Neurochem 106 2008 1866 1875
104. J. Sian-Hulsmann, S. Mandel, M.B. Youdim, and P. Riederer The relevance of iron in the pathogenesis of Parkinson's disease J. Neurochem 118 2011 939 957
105. M. Bougria, J. Vitorica, J. Cano, and A. Machado Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes Eur. J. Pharmacol 291 1995 407 415
106. C. Gomez, M.J. Bandez, and A. Navarro Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome Front. Biosci 12 2007 1079 1093
107. C. Henchcliffe, and M.F. Beal Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 4 2008 600 609
108. A.P. Kudin, N.Y. Bimpong-Buta, S. Vielhaber, C.E. Elger, and W.S. Kunz Characterization of superoxide-producing sites in isolated brain mitochondria J. Biol. Chem. 279 2004 4127 4135
109. B. Janetzky, S. Hauck, M.B. Youdim, P. Riederer, K. Jellinger, and F. Pantucek Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease Neurosci. Lett 169 1994 126 128
110. A.H. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease J. Neurochem. 54 1990 823 827
111. A.H. Schapira, J.M. Cooper, D. Dexter, P. Jenner, J.B. Clark, and C.D. Marsden Mitochondrial complex I deficiency in Parkinson's disease Lancet 1 1989 1269
112. V.M. Mann, J.M. Cooper, D. Krige, S.E. Daniel, A.H. Schapira, and Marsden C.D. Brain skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease Brain 115 Pt 2 1992 333 342
113. A. Navarro, A. Boveris, M.J. Bandez, M.J. Sanchez-Pino, C. Gomez, and G. Muntane Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies Free Radic. Biol. Med 46 2009 1574 1580
114. P.M. Keeney, J. Xie, R.A. Capaldi, and J.P. Bennett Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled J. Neurosci 26 2006 5256 5264
115. C. Szabo, H. Ischiropoulos, and R. Radi Peroxynitrite: biochemistry, pathophysiology and development of therapeutics Nat. Rev. Drug Discovery 6 2007 662 680
116. G.C. Brown, and V. Borutaite Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols Biochim. Biophys. Acta 44-49 1658 2004
117. T.G. Hastings The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease J. Bioenerg. Biomembr 41 2009 469 472
118. R.G. Staal, E.V. Mosharov, and D. Sulzer Dopamine neurons release transmitter via a flickering fusion pore Nat. Neurosci. 7 2004 341 346
119. W.M. Caudle, R.E. Colebrooke, P.C. Emson, and G.W. Miller Altered vesicular dopamine storage in Parkinson's disease: a premature demise Trends Neurosci. 31 2008 303 308
120. E.V. Mosharov, R.G. Staal, J. Bove, D. Prou, A. Hananiya, and D. Markov α-Synuclein overexpression increases cytosolic catecholamine concentration J. Neurosci. 26 2006 9304 9311
121. J.C. Shih, K. Chen, and M.J. Ridd Monoamine oxidase: from genes to behavior Annu. Rev. Neurosci. 22 1999 197 217
122. A.H. Stokes, T.G. Hastings, and K.E. Vrana Cytotoxic and genotoxic potential of dopamine J. Neurosci. Res. 55 1999 659 665
123. J.R. Mazzulli, A.J. Mishizen, B.I. Giasson, D.R. Lynch, S.A. Thomas, and A. Nakashima Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates J. Neurosci 26 2006 10068 10078
124. M.J. LaVoie, B.L. Ostaszewski, A. Weihofen, M.G. Schlossmacher, and D.J. Selkoe Dopamine covalently modifies and functionally inactivates parkin Nat. Med 11 2005 1214 1221
125. V.S. Van Laar, A.J. Mishizen, M. Cascio, and T.G. Hastings Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells Neurobiol. Dis 34 2009 487 500
126. D.M. Kuhn, R.E. Arthur Jr., D.M. Thomas, and L.A. Elferink Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease J. Neurochem 73 1999 1309 1317
127. K.A. Conway, J.C. Rochet, R.M. Bieganski, and P.T. Lansbury Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct Science 294 2001 1346 1349
128. G. Mauceli, C.I. Busceti, A. Pellegrini, P. Soldani, P. Lenzi, and A. Paparelli Overexpression of α-synuclein following methamphetamine: is it good or bad? Ann. N. Y. Acad. Sci. 1074 2006 191 197
129. J. Xu, S.Y. Kao, F.J. Lee, W. Song, L.W. Jin, and B.A. Yankner Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease Nat. Med 8 2002 600 606
130. F.J. Lee, F. Liu, Z.B. Pristupa, and H.B. Niznik Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis FASEB J 15 2001 916 926
131. P.P. Michel, M. Ruberg, and E. Hirsch Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease? Sci. STKE 2006 2006 e19
132. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S26 S36
133. J.T. Greenamyre, and T.G. Hastings Parkinson's - divergent causes, convergent mechanisms Science 304 2004 1120 1122
134. C. Volbracht, B.J. van, C. Zhu, K. Blomgren, and M. Leist Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity Eur. J. Neurosci 23 2006 2611 2622
135. L. Turski, K. Bressler, K.J. Rettig, P.A. Loschmann, and H. Wachtel Protection of substantia nigra from MPP neurotoxicity by N-methyl-D-aspartate antagonists Nature 349 1991 414 418
136. A. Zuddas, G. Oberto, F. Vaglini, F. Fascetti, F. Fornai, and G.U. Corsini MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates J. Neurochem. 59 1992 733 739
137. A. Tabatabaei, T.L. Perry, S. Hansen, and C. Krieger Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice Neurosci. Lett 141 1992 192 194
138. E. Brouillet, and M.F. Beal NMDA antagonists partially protect against MPTP induced neurotoxicity in mice Neuroreport 4 1993 387 390
139. K.A. Johnson, P.J. Conn, and C.M. Niswender Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord. Drug Targets 8 2009 475 491
140. J.T. Greenamyre Glutamatergic influences on the basal ganglia Clin. Neuropharmacol. 24 2001 65 70
141. J.G. McCormack, A.P. Halestrap, and R.M. Denton Role of calcium ions in regulation of mammalian intramitochondrial metabolism Physiol. Rev. 70 1990 391 425
142. A.J. Kowaltowski, N.C. de Souza-Pinto, R.F. Castilho, and A.E. Vercesi Mitochondria and reactive oxygen species Free Radic. Biol. Med. 47 2009 333 343
143. J.P. Sheehan, R.H. Swerdlow, W.D. Parker, S.W. Miller, R.E. Davis, and J.B. Tuttle Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease J. Neurochem. 68 1997 1221 1233
144. A.R. Esteves, D.M. Arduino, R.H. Swerdlow, C.R. Oliveira, and S.M. Cardoso Oxidative stress involvement in α-synuclein oligomerization in Parkinson's disease cybrids Antioxid. Redox Signaling 11 2009 439 448
145. C.B. Lucking, A. Durr, V. Bonifati, J. Vaughan, M.G. De, and T. Gasser Association between early-onset Parkinson's disease and mutations in the parkin gene N. Engl. J. Med. 342 2000 1560 1567
146. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 2003 256 259
147. E.M. Valente, P.M. Abou-Sleiman, V. Caputo, M.M. Muqit, K. Harvey, and S. Gispert Hereditary early-onset Parkinson's disease caused by mutations in PINK1 Science 304 2004 1158 1160
148. C. Henchcliffe, and M.F. Beal Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 4 2008 600 609
149. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease Nat. Genet 18 1998 106 108
150. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia Ann. Neurol. 55 2004 164 173
151. K. Ueda, H. Fukushima, E. Masliah, Y. Xia, A. Iwai, and M. Yoshimoto Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease Proc. Natl. Acad. Sci. USA 90 1993 11282 11286
152. B.I. Giasson, I.V. Murray, J.Q. Trojanowski, and V.M. Lee A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly J. Biol. Chem 276 2001 2380 2386
153. D.L. Fortin, M.D. Troyer, K. Nakamura, S. Kubo, M.D. Anthony, and R.H. Edwards Lipid rafts mediate the synaptic localization of α-synuclein J. Neurosci. 24 2004 6715 6723
154. D. Eliezer, E. Kutluay, R. Bussell Jr., and G. Browne Conformational properties of α-synuclein in its free and lipid-associated states J. Mol. Biol 307 2001 1061 1073
155. J.M. George, H. Jin, W.S. Woods, and D.F. Clayton Characterization of a novel protein regulated during the critical period for song learning in the zebra finch Neuron 15 1995 361 372
156. A. Abeliovich, Y. Schmitz, I. Farinas, D. Choi-Lundberg, W.H. Ho, and P.E. Castillo Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 2000 239 252
157. A. Sidhu, C. Wersinger, and P. Vernier Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18 2004 637 647
158. D. Sulzer Clues to how α-synuclein damages neurons in Parkinson's disease Mov. Disord 25 Suppl. 1 2010 S27 S31
159. E.H. Norris, B.I. Giasson, R. Hodara, S. Xu, J.Q. Trojanowski, and H. Ischiropoulos Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations J. Biol. Chem. 280 2005 21212 21219
160. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, and J.C. Kessler Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
161. D. Sulzer Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease Trends Neurosci 30 2007 244 250
162. M.C. Bennett, J.F. Bishop, Y. Leng, P.B. Chock, T.N. Chase, and M.M. Mouradian Degradation of α-synuclein by proteasome J. Biol. Chem. 274 1999 33855 33858
163. G.K. Tofaris, R. Layfield, and M.G. Spillantini α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome FEBS Lett 509 2001 22 26
164. H.J. Rideout, K.E. Larsen, D. Sulzer, and L. Stefanis Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells J. Neurochem 78 2001 899 908
165. H.J. Rideout, and L. Stefanis Proteasomal inhibition-induced inclusion formation and death in cortical neurons require transcription and ubiquitination Mol. Cell. Neurosci 21 2002 223 238
166. E. Paxinou, Q. Chen, M. Weisse, B.I. Giasson, E.H. Norris, and S.M. Rueter Induction of α-synuclein aggregation by intracellular nitrative insult J. Neurosci. 21 2001 8053 8061
167. J.L. Webb, B. Ravikumar, J. Atkins, J.N. Skepper, and D.C. Rubinsztein α-Synuclein is degraded by both autophagy and the proteasome J. Biol. Chem. 278 2003 25009 25013
168. H.J. Lee, F. Khoshaghideh, S. Patel, and S.J. Lee Clearance of α-synuclein oligomeric intermediates via the lysosomal degradation pathway J. Neurosci 24 2004 1888 1896
169. Z.H. Cheung, and N.Y. Ip The emerging role of autophagy in Parkinson's disease Mol. Brain 2 2009 29
170. A.M. Cuervo, L. Stefanis, R. Fredenburg, P.T. Lansbury, and D. Sulzer Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy Science 305 2004 1292 1295
171. L. Petrucelli, C. O'Farrell, P.J. Lockhart, M. Baptista, K. Kehoe, and L. Vink Parkin protects against the toxicity associated with mutant α-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons Neuron 36 2002 1007 1019
172. H. Snyder, K. Mensah, C. Theisler, J. Lee, A. Matouschek, and B. Wolozin Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function J. Biol. Chem 278 2003 11753 11759
173. Y. Tanaka, S. Engelender, S. Igarashi, R.K. Rao, T. Wanner, and R.E. Tanzi Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis Hum. Mol. Genet 10 2001 919 926
174. T. Vogiatzi, M. Xilouri, K. Vekrellis, and L. Stefanis Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells J. Biol. Chem 283 2008 23542 23556
175. Y. Zhang, V.L. Dawson, and T.M. Dawson Oxidative stress and genetics in the pathogenesis of Parkinson's disease Neurobiol. Dis 7 2000 240 250
176. M. Hashimoto, A. Takeda, L.J. Hsu, T. Takenouchi, and E. Masliah Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease J. Biol. Chem 274 1999 28849 28852
177. E.H. Norris, K. Uryu, S. Leight, B.I. Giasson, J.Q. Trojanowski, and V.M. Lee Pesticide exposure exacerbates α-synucleinopathy in an A53T transgenic mouse model Am. J. Pathol. 170 2007 658 666
178. A.B. Manning-Bog, A.L. McCormack, J. Li, V.N. Uversky, A.L. Fink, and D.A. Di Monte The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein J. Biol. Chem 277 2002 1641 1644
179. W. Dauer, N. Kholodilov, M. Vila, A.C. Trillat, R. Goodchild, and K.E. Larsen Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP Proc. Natl. Acad. Sci. USA 99 2002 14524 14529
180. S.V. Kalivendi, D. Yedlapudi, C.J. Hillard, and B. Kalyanaraman Oxidants induce alternative splicing of α-synuclein: implications for Parkinson's disease Free Radic. Biol. Med. 48 2010 377 383
181. L. Devi, V. Raghavendran, B.M. Prabhu, N.G. Avadhani, and H.K. Anandatheerthavarada Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J. Biol. Chem 283 2008 9089 9100
182. N.B. Cole, D. Dieuliis, P. Leo, D.C. Mitchell, and R.L. Nussbaum Mitochondrial translocation of α-synuclein is promoted by intracellular acidification Exp. Cell Res. 314 2008 2076 2089
183. S. Shavali, H.M. Brown-Borg, M. Ebadi, and J. Porter Mitochondrial localization of α-synuclein protein in α-synuclein overexpressing cells Neurosci. Lett 439 2008 125 128
184. M.S. Parihar, A. Parihar, M. Fujita, M. Hashimoto, and P. Ghafourifar α-Synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells Int. J. Biochem. Cell Biol 41 2009 2015 2024
185. L.J. Martin, Y. Pan, A.C. Price, W. Sterling, N.G. Copeland, and N.A. Jenkins Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death J. Neurosci 26 2006 41 50
186. M.S. Parihar, A. Parihar, M. Fujita, M. Hashimoto, and P. Ghafourifar Mitochondrial association of α-synuclein causes oxidative stress Cell. Mol. Life Sci. 65 2008 1272 1284
187. S. Buttner, A. Bitto, J. Ring, M. Augsten, P. Zabrocki, and T. Eisenberg Functional mitochondria are required for α-synuclein toxicity in aging yeast J. Biol. Chem 283 2008 7554 7560
188. J.P. Anderson, D.E. Walker, J.M. Goldstein, L.R. de, K. Banducci, and R.J. Caccavello Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease J. Biol. Chem 281 2006 29739 29752
189. M. Baba, S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, and V.M. Lee Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies Am. J. Pathol 152 1998 879 884
190. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, and M.S. Goldberg α-Synuclein is phosphorylated in synucleinopathy lesions Nat. Cell Biol. 4 2002 160 164
191. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, and H.I. Hurtig Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
192. M. Hasegawa, H. Fujiwara, T. Nonaka, K. Wakabayashi, H. Takahashi, and V.M. Lee Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions J. Biol. Chem. 277 2002 49071 49076
193. G.K. Tofaris, A. Razzaq, B. Ghetti, K.S. Lilley, and M.G. Spillantini Ubiquitination of α-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function J. Biol. Chem 278 2003 44405 44411
194. D.G. Healy, M. Falchi, S.S. O'Sullivan, V. Bonifati, A. Durr, and S. Bressman Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol 7 2008 583 590
195. I.F. Mata, W.J. Wedemeyer, M.J. Farrer, J.P. Taylor, and K.A. Gallo LRRK2 in Parkinson's disease: protein domains and functional insights Trends Neurosci. 29 2006 286 293
196. L. Bosgraaf, and Van Haastert P.J. Roc a Ras/GTPase domain in complex proteins Biochim. Biophys. Acta 1643 2003 5 10
197. E. Greggio, I. Zambrano, A. Kaganovich, A. Beilina, J.M. Taymans, and V. Daniels The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation J. Biol. Chem 283 2008 16906 16914
198. Y. Imai, S. Gehrke, H.Q. Wang, R. Takahashi, K. Hasegawa, and E. Oota Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila EMBO J 27 2008 2432 2443
199. M. Jaleel, R.J. Nichols, M. Deak, D.G. Campbell, F. Gillardon, and A. Knebel LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity Biochem. J 405 2007 307 317
200. A.B. West, D.J. Moore, S. Biskup, A. Bugayenko, W.W. Smith, and C.A. Ross Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. USA 102 2005 16842 16847
201. L. Guo, P.N. Gandhi, W. Wang, R.B. Petersen, A.L. Wilson-Delfosse, and S.G. Chen The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity Exp. Cell Res 313 2007 3658 3670
202. G. Ito, T. Okai, G. Fujino, K. Takeda, H. Ichijo, and T. Katada GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease Biochemistry 46 2007 1380 1388
203. L.F. Burbulla, and R. Kruger Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease J. Neurol. Sci 306 2011 1 8
204. W.W. Smith, Z. Pei, H. Jiang, V.L. Dawson, T.M. Dawson, and C.A. Ross Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9 2006 1231 1233
205. F.A. Di, C.F. Rohe, J. Ferreira, H.F. Chien, L. Vacca, and F. Stocchi A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease Lancet 365 2005 412 415
206. W.P. Gilks, P.M. Abou-Sleiman, S. Gandhi, S. Jain, A. Singleton, and A.J. Lees A common LRRK2 mutation in idiopathic Parkinson's disease Lancet 365 2005 415 416
207. W.C. Nichols, N. Pankratz, D. Hernandez, C. Paisan-Ruiz, S. Jain, and C.A. Halter Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease Lancet 365 2005 410 412
208. B.I. Giasson, J.P. Covy, N.M. Bonini, H.I. Hurtig, M.J. Farrer, and J.Q. Trojanowski Biochemical and pathological characterization of Lrrk2 Ann. Neurol. 59 2006 315 322
209. O.A. Ross, M. Toft, A.J. Whittle, J.L. Johnson, S. Papapetropoulos, and D.C. Mash Lrrk2 and Lewy body disease Ann. Neurol. 59 2006 388 393
210. Y. Tong, H. Yamaguchi, E. Giaime, S. Boyle, R. Kopan, and R.J. Kelleher III Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice Proc. Natl. Acad. Sci. USA 107 2010 9879 9884
211. H. Mortiboys, K.K. Johansen, J.O. Aasly, and O. Bandmann Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 Neurology 75 2010 2017 2020
212. H.N. Nguyen, B. Byers, B. Cord, A. Shcheglovitov, J. Byrne, and P. Gujar LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Cell Stem Cell 8 2011 267 280
213. C. Criscuolo, G. Volpe, R.A. De, A. Varrone, R. Marongiu, and P. Mancini PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism Mov. Disord 21 2006 1265 1267
214. C.B. Lucking, V. Bonifati, M. Periquet, N. Vanacore, A. Brice, and G. Meco Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations Neurology 57 2001 924 927
215. M. Maruyama, T. Ikeuchi, M. Saito, A. Ishikawa, T. Yuasa, and H. Tanaka Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism Ann. Neurol 48 2000 245 250
216. C.B. Lucking, V. Chesneau, E. Lohmann, P. Verpillat, C. Dulac, and A.M. Bonnet Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease Arch. Neurol 60 2003 1253 1256
217. M. Periquet, M. Latouche, E. Lohmann, N. Rawal, M.G. De, and S. Ricard Parkin mutations are frequent in patients with isolated early-onset parkinsonism Brain 126 2003 1271 1278
218. H. Takahashi, E. Ohama, S. Suzuki, Y. Horikawa, A. Ishikawa, and T. Morita Familial juvenile parkinsonism: clinical and pathologic study in a family Neurology 44 1994 437 441
219. M. Farrer, P. Chan, R. Chen, L. Tan, S. Lincoln, and D. Hernandez Lewy bodies and parkinsonism in families with parkin mutations Ann. Neurol 50 2001 293 300
220. D.J. Moore Parkin: a multifaceted ubiquitin ligase Biochem. Soc. Trans. 34 2006 749 753
221. H. Shimura, M.G. Schlossmacher, N. Hattori, M.P. Frosch, A. Trockenbacher, and R. Schneider Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease Science 293 2001 263 269
222. O. Corti, C. Hampe, H. Koutnikova, F. Darios, S. Jacquier, and A. Prigent The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration Hum. Mol. Genet 12 2003 1427 1437
223. C.R. von, V.L. Dawson, and T.M. Dawson Parkin-associated Parkinson's disease Cell Tissue Res. 318 2004 175 184
224. H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, and S. Minoshima Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat. Genet. 25 2000 302 305
225. S.I. Kubo, T. Kitami, S. Noda, H. Shimura, Y. Uchiyama, and S. Asakawa Parkin is associated with cellular vesicles J. Neurochem. 78 2001 42 54
226. A. Mouatt-Prigent, M.P. Muriel, W.J. Gu, K.H. El Hachimi, C.B. Lucking, and A. Brice Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia J. Neural Transm. 111 2004 1209 1218
227. F. Darios, O. Corti, C.B. Lucking, C. Hampe, M.P. Muriel, and N. Abbas Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death Hum. Mol. Genet 12 2003 517 526
228. M.R. Cookson, P.J. Lockhart, C. McLendon, C. O'Farrell, M. Schlossmacher, and M.J. Farrer RING finger 1 mutations in Parkin produce altered localization of the protein Hum. Mol. Genet 12 2003 2957 2965
229. W.J. Gu, O. Corti, F. Araujo, C. Hampe, S. Jacquier, and C.B. Lucking The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates Neurobiol. Dis 14 2003 357 364
230. C. Wang, J.M. Tan, M.W. Ho, N. Zaiden, S.H. Wong, and C.L. Chew Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations J. Neurochem 93 2005 422 431
231. Y. Kuroda, T. Mitsui, M. Kunishige, M. Shono, M. Akaike, and H. Azuma Parkin enhances mitochondrial biogenesis in proliferating cells Hum. Mol. Genet 15 2006 883 895
232. J.J. Palacino, D. Sagi, M.S. Goldberg, S. Krauss, C. Motz, and M. Wacker Mitochondrial dysfunction and oxidative damage in parkin-deficient mice J. Biol. Chem. 279 2004 18614 18622
233. C.C. Stichel, X.R. Zhu, V. Bader, B. Linnartz, S. Schmidt, and H. Lubbert Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage Hum. Mol. Genet 16 2007 2377 2393
234. J.C. Greene, A.J. Whitworth, I. Kuo, L.A. Andrews, M.B. Feany, and L.J. Pallanck Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants Proc. Natl. Acad. Sci. USA 100 2003 4078 4083
235. Y. Pesah, T. Pham, H. Burgess, B. Middlebrooks, P. Verstreken, and Y. Zhou Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress Development 131 2004 2183 2194
236. Y. Machida, T. Chiba, A. Takayanagi, Y. Tanaka, M. Asanuma, and N. Ogawa Common anti-apoptotic roles of parkin and α-synuclein in human dopaminergic cells Biochem. Biophys. Res. Commun 332 2005 233 240
237. O. Rothfuss, H. Fischer, T. Hasegawa, M. Maisel, P. Leitner, and F. Miesel Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair Hum. Mol. Genet 18 2009 3832 3850
238. E.M. Valente, A.R. Bentivoglio, P.H. Dixon, A. Ferraris, T. Ialongo, and M. Frontali Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36 Am. J. Hum. Genet. 68 2001 895 900
239. V. Bonifati, C.F. Rohe, G.J. Breedveld, E. Fabrizio, M.M. De, and C. Tassorelli Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes Neurology 65 2005 87 95
240. E.K. Tan, K. Yew, E. Chua, K. Puvan, H. Shen, and E. Lee PINK1 mutations in sporadic early-onset Parkinson's disease Mov. Disord 21 2006 789 793
241. Y. Hatano, K. Sato, B. Elibol, H. Yoshino, Y. Yamamura, and V. Bonifati PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations Neurology 63 2004 1482 1485
242. S. Gandhi, M.M. Muqit, L. Stanyer, D.G. Healy, P.M. Abou-Sleiman, and I. Hargreaves PINK1 protein in normal human brain and Parkinson's disease Brain 129 2006 1720 17231
243. N. Exner, B. Treske, D. Paquet, K. Holmstrom, C. Schiesling, and S. Gispert Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin J. Neurosci 27 2007 12413 12418
244. M. Atsumi, Y. Li, H. Tomiyama, K. Sato, and N. Hattori [A 62-year-old woman with early-onset Parkinson's disease associated with the PINKi gene deletion] Rinsho Shinkeigaku 46 2006 199 202
245. E.M. Valente, S. Salvi, T. Ialongo, R. Marongiu, A.E. Elia, and V. Caputo PINK1 mutations are associated with sporadic early-onset parkinsonism Ann. Neurol. 56 2004 336 341
246. H.H. Hoepken, S. Gispert, B. Morales, O. Wingerter, T.D. Del, and A. Mulsch Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6 Neurobiol. Dis. 25 2007 401 411
247. I.E. Clark, M.W. Dodson, C. Jiang, J.H. Cao, J.R. Huh, and J.H. Seol Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin Nature 441 2006 1162 1166
248. A. Petit, T. Kawarai, E. Paitel, N. Sanjo, M. Maj, and M. Scheid Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations J. Biol. Chem 280 2005 34025 34032
249. A. Wood-Kaczmar, S. Gandhi, Z. Yao, A.Y. Abramov, E.A. Miljan, and G. Keen PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons PLoS One 3 2008 e2455
250. J. Park, S.B. Lee, S. Lee, Y. Kim, S. Song, and S. Kim Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin Nature 441 2006 1157 1161
251. Y. Yang, S. Gehrke, Y. Imai, Z. Huang, Y. Ouyang, and J.W. Wang Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin Proc. Natl. Acad. Sci. USA 103 2006 10793 10798
252. S.J. Goldman, R. Taylor, Y. Zhang, and S. Jin Autophagy and the degradation of mitochondria Mitochondrion 10 2010 309 315
253. I. Kim, S. Rodriguez-Enriquez, and J.J. Lemasters Selective degradation of mitochondria by mitophagy Arch. Biochem. Biophys. 462 2007 245 253
254. D. Narendra, A. Tanaka, D.F. Suen, and R.J. Youle Parkin is recruited selectively to impaired mitochondria and promotes their autophagy J. Cell Biol 183 2008 795 803
255. D.P. Narendra, S.M. Jin, A. Tanaka, D.F. Suen, C.A. Gautier, and J. Shen PINK1 is selectively stabilized on impaired mitochondria to activate Parkin PLoS Biol. 8 2010 e1000298
256. N. Matsuda, S. Sato, K. Shiba, K. Okatsu, K. Saisho, and C.A. Gautier PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy J. Cell Biol 189 2010 211 221
257. Q. Ruan, A.J. Harrington, K.A. Caldwell, G.A. Caldwell, and D.G. Standaert VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease Neurobiol. Dis 37 2010 330 338
258. H. Deng, M.W. Dodson, H. Huang, and M. Guo The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila Proc. Natl. Acad. Sci. USA 105 2008 14503 14508
259. A.C. Poole, R.E. Thomas, L.A. Andrews, H.M. McBride, A.J. Whitworth, and L.J. Pallanck The PINK1/Parkin pathway regulates mitochondrial morphology Proc. Natl. Acad. Sci. USA 105 2008 1638 1643
260. A. Grunewald, M.E. Gegg, J.W. Taanman, R.H. King, N. Kock, and C. Klein Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology Exp. Neurol. 219 2009 266 273
261. H. Mortiboys, K.J. Thomas, W.J. Koopman, S. Klaffke, P. Abou-Sleiman, and S. Olpin Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts Ann. Neurol 64 2008 555 565
262. C. Piccoli, A. Sardanelli, R. Scrima, M. Ripoli, G. Quarato, and A. D'Aprile Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation Neurochem. Res 33 2008 2565 2574
263. D.J. Moore, L. Zhang, T.M. Dawson, and V.L. Dawson A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization J. Neurochem 87 2003 1558 1567
264. L. Zhang, M. Shimoji, B. Thomas, D.J. Moore, S.W. Yu, and N.I. Marupudi Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis Hum. Mol. Genet 14 2005 2063 2073
265. D. Nagakubo, T. Taira, H. Kitaura, M. Ikeda, K. Tamai, and S.M. Iguchi-Ariga DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras Biochem. Biophys. Res. Commun 231 1997 509 513
266. P.M. Abou-Sleiman, D.G. Healy, N. Quinn, A.J. Lees, and N.W. Wood The role of pathogenic DJ-1 mutations in Parkinson's disease Ann. Neurol. 54 2003 283 286
267. R.M. Canet-Aviles, M.A. Wilson, D.W. Miller, R. Ahmad, C. McLendon, and S. Bandyopadhyay The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization Proc. Natl. Acad. Sci. USA 101 2004 9103 9108
268. D.J. Moore, L. Zhang, J. Troncoso, M.K. Lee, N. Hattori, and Y. Mizuno Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress Hum. Mol. Genet 14 2005 71 84
269. V. Bonifati, P. Rizzu, F. Squitieri, E. Krieger, N. Vanacore, and J.C. van Swieten DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism Neurol. Sci. 24 2003 159 160
270. T. Taira, Y. Saito, T. Niki, S.M. Iguchi-Ariga, K. Takahashi, and H. Ariga DJ-1 has a role in antioxidative stress to prevent cell death EMBO Rep 5 2004 213 218
271. R. Hering, K.M. Strauss, X. Tao, A. Bauer, D. Woitalla, and E.M. Mietz Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) Hum. Mutat. 24 2004 321 329
272. N. Lev, D. Ickowicz, E. Melamed, and D. Offen Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection Neurotoxicology 29 2008 397 405
273. M. Meulener, A.J. Whitworth, C.E. Armstrong-Gold, P. Rizzu, P. Heutink, and P.D. Wes Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease Curr. Biol 15 2005 1572 1577
274. J. Park, S.Y. Kim, G.H. Cha, S.B. Lee, S. Kim, and J. Chung Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction Gene 361 2005 133 139
275. M.C. Meulener, K. Xu, L. Thomson, H. Ischiropoulos, and N.M. Bonini Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging Proc. Natl. Acad. Sci. USA 103 2006 12517 12522
276. R.H. Kim, P.D. Smith, H. Aleyasin, S. Hayley, M.P. Mount, and S. Pownall Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress Proc. Natl. Acad. Sci. USA 102 2005 5215 5220
277. C. Martinat, S. Shendelman, A. Jonason, T. Leete, M.F. Beal, and L. Yang Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary parkinsonism PLoS Biol. 2 2004 e327
278. S. Shendelman, A. Jonason, C. Martinat, T. Leete, and A. Abeliovich DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation PLoS Biol. 2 2004 e362
279. W. Yang, L. Chen, Y. Ding, X. Zhuang, and U.J. Kang Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice Hum. Mol. Genet 16 2007 2900 2910
280. J.Y. Im, K.W. Lee, E. Junn, and M.M. Mouradian DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex Neurosci. Res 67 2010 203 208
281. T. Hayashi, C. Ishimori, K. Takahashi-Niki, T. Taira, Y.C. Kim, and H. Maita DJ-1 binds to mitochondrial complex I and maintains its activity Biochem. Biophys. Res. Commun. 390 2009 667 672
282. G. Krebiehl, S. Ruckerbauer, L.F. Burbulla, N. Kieper, B. Maurer, and J. Waak Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1 PLoS One 5 2010 e9367
283. T. Cunha-Oliveira, A.C. Rego, and C.R. Oliveira Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs Brain Res. Rev 58 2008 192 208
284. M. San Luciano, and R. Saunders-Pullman Substance abuse and movement disorders Curr. Drug Abuse Rev 2 2009 273 278
285. J.C. Brust Substance abuse and movement disorders Mov. Disord 25 2010 2010 2020
286. R.C. Callaghan, J.K. Cunningham, J. Sykes, and S.J. Kish Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs Drug Alcohol Depend 120 2012 35 40
287. D. Sulzer How addictive drugs disrupt presynaptic dopamine neurotransmission Neuron 69 2011 628 649
288. M. Carvalho, H. Carmo, V.M. Costa, J.P. Capela, H. Pontes, and F. Remiao Toxicity of amphetamines: an update Arch. Toxicol. 86 2012 1167 1231
289. H.H. Sitte, S. Huck, H. Reither, S. Boehm, E.A. Singer, and C. Pifl Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter J. Neurochem 71 1998 1289 1297
290. S.R. Jones, J.D. Joseph, L.S. Barak, M.G. Caron, and R.M. Wightman Dopamine neuronal transport kinetics and effects of amphetamine J. Neurochem. 73 1999 2406 2414
291. D. Sulzer, T.K. Chen, Y.Y. Lau, H. Kristensen, S. Rayport, and A. Ewing Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J. Neurosci 15 1995 4102 4108
292. K.M. Kahlig, F. Binda, H. Khoshbouei, R.D. Blakely, D.G. McMahon, and J.A. Javitch Amphetamine induces dopamine efflux through a dopamine transporter channel Proc. Natl. Acad. Sci. USA 102 2005 3495 3500
293. D. Sulzer, M.S. Sonders, N.W. Poulsen, and A. Galli Mechanisms of neurotransmitter release by amphetamines: a review Prog. Neurobiol. 75 2005 406 433
294. R.R. Ramsay, and D.J. Hunter Inhibitors alter the spectrum and redox properties of monoamine oxidase A. Biochim. Biophys. Acta 178-184 1601 2002
295. G. Ellison, M.S. Eison, H.S. Huberman, and F. Daniel Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration Science 201 1978 276 278
296. T. Cunha-Oliveira, A.C. Rego, M.T. Morgadinho, T. Macedo, and C.R. Oliveira Differential cytotoxic responses of PC12 cells chronically exposed to psychostimulants or to hydrogen peroxide Toxicology 217 2006 54 62
297. T.R. Guilarte Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22 2001 725 731
298. H. Kobayashi, S. Ide, J. Hasegawa, H. Ujike, Y. Sekine, and N. Ozaki Study of association between α-synuclein gene polymorphism and methamphetamine psychosis/dependence Ann. N. Y. Acad. Sci. 1025 2004 325 334
299. F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, and L. Capobianco Similarities between methamphetamine toxicity and proteasome inhibition Ann. N. Y. Acad. Sci. 1025 2004 162 170
300. L. Iacovelli, F. Fulceri, B.A. De, F. Nicoletti, S. Ruggieri, and F. Fornai The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders Exp. Neurol. 201 2006 24 31
301. T.B. Sherer, J.H. Kim, R. Betarbet, and J.T. Greenamyre Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation Exp. Neurol 179 2003 9 16
302. F. Fornai, O.M. Schluter, P. Lenzi, M. Gesi, R. Ruffoli, and M. Ferrucci Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein Proc. Natl. Acad. Sci. USA 102 2005 3413 3418
303. F. Fornai, P. Lenzi, M. Ferrucci, G. Lazzeri, A.B. di Poggio, and G. Natale Occurrence of neuronal inclusions combined with increased nigral expression of α-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice Brain Res. Bull 65 2005 405 413
304. M. Vila, S. Vukosavic, V. Jackson-Lewis, M. Neystat, M. Jakowec, and S. Przedborski α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP J. Neurochem 74 2000 721 729
305. B.D. Jung, E.J. Shin, X.K. Nguyen, C.H. Jin, J.H. Bach, and S.J. Park Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration Neurochem. Int. 56 2010 229 244
306. B.K. Yamamoto, and M.G. Bankson Amphetamine neurotoxicity: cause and consequence of oxidative stress Crit. Rev. Neurobiol. 17 2005 87 117
307. J.L. Cadet, I.N. Krasnova, S. Jayanthi, and J. Lyles Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms Neurotox. Res. 11 2007 183 202
308. C.W. Wu, Y.H. Ping, J.C. Yen, C.Y. Chang, S.F. Wang, and C.L. Yeh Enhanced oxidative stress and aberrant mitochondrial biogenesis in human neuroblastoma SH-SY5Y cells during methamphetamine induced apoptosis Toxicol. Appl. Pharmacol. 220 2007 243 251
309. D. Pubill, C. Chipana, A. Camins, M. Pallas, J. Camarasa, and E. Escubedo Free radical production induced by methamphetamine in rat striatal synaptosomes Toxicol. Appl. Pharmacol 204 2005 57 68
310. B.N. Frey, S.S. Valvassori, K.M. Gomes, M.R. Martins, F. Dal-Pizzol, and F. Kapczinski Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure Brain Res. 1097 2006 224 229
311. A. Jimenez, E.G. Jorda, E. Verdaguer, D. Pubill, F.X. Sureda, and A.M. Canudas Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells Toxicol. Appl. Pharmacol 196 2004 223 234
312. A. Mirecki, P. Fitzmaurice, L. Ang, K.S. Kalasinsky, F.J. Peretti, and S.S. Aiken Brain antioxidant systems in human methamphetamine users J. Neurochem. 89 2004 1396 1408
313. O. Acikgoz, S. Gonenc, B.M. Kayatekin, C. Pekcetin, N. Uysal, and A. Dayi The effects of single dose of methamphetamine on lipid peroxidation levels in the rat striatum and prefrontal cortex Eur. Neuropsychopharmacol 10 2000 415 418
314. B.N. Frey, S.S. Valvassori, G.Z. Reus, M.R. Martins, F.C. Petronilho, and K. Bardini Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania Neurochem. Res. 31 2006 699 703
315. F. Carvalho, E. Fernandes, F. Remiao, J. Gomes-Da-Silva, M.A. Tavares, and M.D. Bastos Adaptative response of antioxidant enzymes in different areas of rat brain after repeated d-amphetamine administration Addict. Biol 6 2001 213 221
316. P.S. Fitzmaurice, J. Tong, M. Yazdanpanah, P.P. Liu, K.S. Kalasinsky, and S.J. Kish Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine J. Pharmacol. Exp. Ther 319 2006 703 709
317. T. Cunha-Oliveira, A.C. Rego, M.T. Morgadinho, T. Macedo, and C.R. Oliveira Differential cytotoxic responses of PC12 cells chronically exposed to psychostimulants or to hydrogen peroxide Toxicology 217 2006 54 62
318. A. El Avadi, and M.J. Zigmond Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study PLoS One 6 2011 e24722